Elisabeth I Heath Selected Research

Disease Progression

1/2023	Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.
11/2020	Exploring Spatial-Temporal Changes in 18F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide.
1/2020	An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer.
2/2016	A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.
4/2013	A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.
1/2013	Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Elisabeth I Heath Research Topics

Disease

62	Prostatic Neoplasms (Prostate Cancer) 04/2024 - 09/2005
55	Neoplasms (Cancer) 05/2024 - 04/2007
10	Carcinoma (Carcinomatosis) 01/2022 - 02/2002
7	Carcinogenesis 04/2024 - 08/2006
7	Neoplasm Metastasis (Metastasis) 01/2023 - 10/2016
6	Disease Progression 01/2023 - 01/2013
5	Renal Cell Carcinoma (Grawitz Tumor) 01/2023 - 01/2014
5	Adenocarcinoma 01/2022 - 02/2002
5	Fatigue 01/2022 - 10/2019
5	Circulating Neoplastic Cells 01/2022 - 01/2013
4	Pain (Aches) 12/2023 - 12/2010
3	Hypoxia (Hypoxemia) 12/2019 - 03/2008
3	Exanthema (Rash) 10/2019 - 04/2007
3	Barrett Esophagus (Barrett's Esophagus) 01/2009 - 04/2007
3	Esophageal Neoplasms (Esophageal Cancer) 04/2007 - 02/2002
2	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2018
2	Abdominal Pain (Pain, Abdominal) 01/2022 - 10/2019
2	DNA Repair-Deficiency Disorders (Chromosome Instability Syndromes) 01/2022 - 01/2018
2	Neutropenia 10/2019 - 10/2019
2	Diarrhea 10/2019 - 04/2007
2	Hypertension (High Blood Pressure) 03/2016 - 01/2016
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2012 - 04/2007
1	Alopecia (Baldness) 03/2024
1	Body Weight (Weight, Body) 10/2023
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 08/2023
1	Margins of Excision 01/2023
1	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 01/2022
1	Anemia 01/2022
1	Vomiting 01/2022

Drug/Important Bio-Agent (IBA)

11	AndrogensIBA 01/2023 - 01/2013
10	Biomarkers (Surrogate Marker)IBA 08/2023 - 10/2009
9	Hormones (Hormone)IBA 01/2024 - 09/2005
8	Prostate-Specific Antigen (Semenogelase)IBA 11/2023 - 07/2007
7	enzalutamideIBA 01/2023 - 10/2018
7	Proteins (Proteins, Gene)FDA Link 06/2021 - 03/2008
6	Docetaxel (Taxotere)FDA Link 03/2024 - 02/2002
6	Celecoxib (Celebrex)FDA Link 10/2009 - 12/2002
5	DNA (Deoxyribonucleic Acid)IBA 04/2024 - 01/2018
5	Tyrosine Kinase InhibitorsIBA 01/2023 - 04/2007
5	PlatinumIBA 01/2022 - 04/2007
5	enfortumab vedotinIBA 01/2022 - 10/2019
4	Immune Checkpoint InhibitorsIBA 08/2023 - 01/2021
4	Androgen Receptors (Androgen Receptor)IBA 01/2022 - 01/2012
4	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 01/2018
3	RNA (Ribonucleic Acid)IBA 04/2024 - 08/2023
3	taxaneIBA 03/2024 - 10/2019
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2023 - 06/2021
3	Abiraterone AcetateIBA 01/2022 - 01/2021
3	Carboplatin (JM8)FDA LinkGeneric 10/2019 - 09/2011
2	Messenger RNA (mRNA)IBA 05/2024 - 04/2007
2	Everolimus FDA Link 01/2023 - 08/2019
2	pembrolizumabIBA 01/2023 - 01/2021
2	cabozantinibIBA 01/2023 - 01/2019
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2023 - 01/2022
2	Cell-Free Nucleic AcidsIBA 10/2022 - 01/2022
2	Drug CombinationsIBA 01/2022 - 04/2007
2	Histone Deacetylases (Histone Deacetylase)IBA 01/2022 - 12/2018
2	Histone Deacetylase InhibitorsIBA 01/2022 - 12/2018
2	Prednisone (Sone)FDA LinkGeneric 12/2021 - 01/2021
2	bicalutamide (Casodex)FDA LinkGeneric 01/2021 - 05/2015
2	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 01/2021
2	B7-H1 AntigenIBA 10/2019 - 01/2018
2	Anti-Bacterial Agents (Antibiotics)IBA 12/2018 - 12/2008
2	LigandsIBA 10/2018 - 11/2012
2	Cytotoxins (Cytolysins)IBA 01/2018 - 01/2009
2	Gefitinib (Iressa)FDA Link 11/2016 - 04/2007
2	Growth Factor ReceptorsIBA 11/2016 - 08/2006
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2016 - 03/2008
2	pazopanib FDA Link 03/2013 - 08/2012
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2012 - 08/2006
2	Paclitaxel (Taxol)FDA LinkGeneric 12/2011 - 09/2011
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 10/2009 - 04/2007
1	PentosesIBA 04/2024
1	Phosphates (Orthophosphate)IBA 04/2024
1	Fatty Acids (Saturated Fatty Acids)IBA 04/2024
1	antineoplaston A10 (A 10)IBA 12/2023
1	Conjugated (USP) Estrogens (Premarin)FDA Link 11/2023
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 10/2023
1	Sodium Fluoride (Ossin)FDA Link 01/2023
1	olaparibIBA 01/2023
1	belzutifanIBA 01/2023
1	RadiopharmaceuticalsIBA 01/2023
1	vistusertibIBA 01/2022
1	Oxidoreductases (Dehydrogenase)IBA 01/2022
1	TransferasesIBA 01/2022
1	YM753 compoundIBA 01/2022
1	Estrogen ReceptorsIBA 01/2022
1	Ethanol (Ethyl Alcohol)IBA 01/2022
1	Histones (Histone)IBA 01/2022

Therapy/Procedure

38	Therapeutics 05/2024 - 03/2008
24	Castration 04/2024 - 01/2013
12	Drug Therapy (Chemotherapy) 12/2023 - 02/2002
6	Radiotherapy 01/2023 - 02/2002
4	Immunotherapy 04/2024 - 08/2006
4	Prostatectomy (Retropubic Prostatectomy) 01/2023 - 10/2009
4	Chemoprevention 04/2016 - 04/2007
3	Precision Medicine 04/2024 - 05/2015
2	Nephrectomy 01/2023 - 08/2019
1	Salvage Therapy 01/2023
1	Intravenous Infusions 01/2022